Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Regulus Therapeutics (RGLS)

Regulus Therapeutics (RGLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,912
  • Shares Outstanding, K 39,163
  • Annual Sales, $ 6,830 K
  • Annual Income, $ -18,590 K
  • 60-Month Beta 2.31
  • Price/Sales 7.31
  • Price/Cash Flow N/A
  • Price/Book 5.81
Trade RGLS with:

Options Overview

Details
  • Implied Volatility 465.32%
  • Historical Volatility 128.08%
  • IV Percentile 80%
  • IV Rank 33.45%
  • IV High 1,230.37% on 03/16/20
  • IV Low 80.80% on 09/18/20
  • Put/Call Vol Ratio 0.00
  • Today's Volume 13
  • Volume Avg (30-Day) 764
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 2,858
  • Open Int (30-Day) 7,299

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.10
  • Number of Estimates 2
  • High Estimate -0.09
  • Low Estimate -0.10
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +56.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0000 +25.50%
on 03/05/21
1.9700 -36.29%
on 02/17/21
-0.3950 (-23.94%)
since 02/08/21
3-Month
0.8520 +47.30%
on 12/09/20
1.9700 -36.29%
on 02/17/21
+0.3220 (+34.51%)
since 12/08/20
52-Week
0.4222 +197.25%
on 09/08/20
1.9700 -36.29%
on 02/17/21
+0.5800 (+85.93%)
since 03/06/20

Most Recent Stories

More News
Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

, /PRNewswire/ --  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that , President and Chief...

RGLS : 1.2700 (-2.31%)
Will Regulus (RGLS) Report Negative Q4 Earnings? What You Should Know

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RGLS : 1.2700 (-2.31%)
Neptune Wellness Solutions Inc. President Michael Cammarata Named Top 25 Biotech CEO

Neptune Wellness Solutions Inc. President Michael Cammarata Named Top 25 Biotech CEO

ADMA : 2.16 (+3.35%)
ARNA : 73.74 (+0.23%)
BDSI : 4.06 (+0.25%)
CRIS : 9.56 (+0.95%)
RGLS : 1.2700 (-2.31%)
NEPT : 1.4500 (+2.84%)
NEPT.TO : 1.79 (+0.56%)
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

, /PRNewswire/ --  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has...

RGLS : 1.2700 (-2.31%)
Regulus Announces Addition to Board of Directors

, /PRNewswire/ -- (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced , Ph.D. has been appointed to the Company's...

RGLS : 1.2700 (-2.31%)
Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

, /PRNewswire/ --  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that , President and Chief...

RGLS : 1.2700 (-2.31%)
Thinking about buying stock in Inseego Corp, Ampio Pharmaceuticals, Marathon Patent Group, Regulus Therapeutics, or BioCryst Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INSG, AMPE, MARA, RGLS, and BCRX.

AMPE : 1.4800 (-2.03%)
BCRX : 11.49 (+3.05%)
INSG : 9.50 (+1.17%)
RGLS : 1.2700 (-2.31%)
MARA : 32.10 (+6.89%)
Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?

Investors need to pay close attention to Regulus Therapeutics (RGLS) stock based on the movements in the options market lately.

RGLS : 1.2700 (-2.31%)
Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity

, /PRNewswire/ -- . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the closing of its previously announced...

RGLS : 1.2700 (-2.31%)
Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development

, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326,...

RGLS : 1.2700 (-2.31%)
TECH : 360.23 (+1.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and...

See More

Key Turning Points

3rd Resistance Point 1.7000
2nd Resistance Point 1.5000
1st Resistance Point 1.4000
Last Price 1.2700
1st Support Level 1.1000
2nd Support Level 0.9000
3rd Support Level 0.8000

See More

52-Week High 1.9700
Fibonacci 61.8% 1.3787
Last Price 1.2700
Fibonacci 50% 1.1961
Fibonacci 38.2% 1.0135
52-Week Low 0.4222

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar